a Centre for Haemato-Oncology , Barts Cancer Institute, Queen Mary University of London , London , UK.
b Cancer Sciences Unit, Faculty of Medicine , University of Southampton , Southampton , UK.
Expert Rev Mol Diagn. 2016 Oct;16(10):1093-1102. doi: 10.1080/14737159.2016.1235974. Epub 2016 Sep 24.
The adoption of high-throughput technologies has led to a transformation in our ability to classify diffuse large B-cell lymphoma (DLBCL) into unique molecular subtypes. In parallel, the expansion of agents targeting key genetic and gene expression signatures has led to an unprecedented opportunity to personalize cancer therapies, paving the way for precision medicine. Areas covered: This review summarizes the key molecular subtypes of DLBCL and outlines the novel technology platforms in development to discriminate clinically relevant subtypes. Expert commentary: The application of emerging diagnostic tests into routine clinical practise is gaining momentum following the demonstration of subtype specific activity by novel agents. Co-ordinated efforts are required to ensure that these state of the art technologies provide reliable and clinically meaningful results accessible to the wider haematology community.
高通量技术的采用使得我们能够将弥漫性大 B 细胞淋巴瘤 (DLBCL) 分类为独特的分子亚型，这一能力发生了转变。与此同时，针对关键遗传和基因表达特征的靶向药物的扩展，为癌症治疗的个体化提供了前所未有的机会，为精准医学铺平了道路。涵盖领域：本文综述了 DLBCL 的关键分子亚型，并概述了正在开发的用于区分具有临床相关性的亚型的新型技术平台。专家评论：新型药物证实了亚类特异性活性后，将新兴诊断测试应用于常规临床实践正在获得动力。需要协调努力，以确保这些最先进的技术提供可靠且具有临床意义的结果，使更广泛的血液学领域能够获得这些结果。
